-
In Search of COVID-19 Vaccines That Elicit Mucosal Immunity and Stop Transmission JAMA (IF 63.1) Pub Date : 2024-12-20 Rita Rubin
This Medial News article discusses recent research showing that current COVID-19 vaccines fail to elicit enough of a mucosal immune response to prevent infection.
-
Health Systems Are Struggling to Keep Up With AI—A National Registration System Could Help JAMA (IF 63.1) Pub Date : 2024-12-20 Roy Perlis, Rita Rubin
This Medical News article is an interview with Michael Pencina, PhD, Duke Health’s chief data scientist, about the need for health systems to collaborate to keep up with the AI revolution.
-
-
Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infection JAMA (IF 63.1) Pub Date : 2024-12-19 John Flores, Andrew M. Davis, Aniruddha Hazra
This JAMA Guidelines Synopsis summarizes the 2024 Centers for Disease Control and Prevention guidelines on use of doxycycline postexposure prophylaxis (doxyPEP) for bacterial sexually transmitted infection prevention.
-
2024 Update of the RECOVER-Adult Long COVID Research Index. JAMA (IF 63.1) Pub Date : 2024-12-18 Linda N Geng,Kristine M Erlandson,Mady Hornig,Rebecca Letts,Caitlin Selvaggi,Hassan Ashktorab,Ornina Atieh,Logan Bartram,Hassan Brim,Shari B Brosnahan,Jeanette Brown,Mario Castro,Alexander Charney,Peter Chen,Steven G Deeks,Nathaniel Erdmann,Valerie J Flaherman,Maher A Ghamloush,Paul Goepfert,Jason D Goldman,Jenny E Han,Rachel Hess,Ellie Hirshberg,Susan E Hoover,Stuart D Katz,J Daniel Kelly,Jonathan
Importance Classification of persons with long COVID (LC) or post-COVID-19 condition must encompass the complexity and heterogeneity of the condition. Iterative refinement of the classification index for research is needed to incorporate newly available data as the field rapidly evolves. Objective To update the 2023 research index for adults with LC using additional participant data from the Researching
-
-
Unionization Efforts by Physicians Between 2000 and 2024. JAMA (IF 63.1) Pub Date : 2024-12-18 Hayden Rooke-Ley,Barak Richman,Daniel S Bowling,Margaret Nikolov,Kevin Schulman
-
Obesity and Glucagon-Like Peptide-1 Receptor Agonists JAMA (IF 63.1) Pub Date : 2024-12-18 Francesca Celletti, Francesco Branca, Jeremy Farrar
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
-
Adolescent-Centered Sexual and Reproductive Health Communication JAMA (IF 63.1) Pub Date : 2024-12-18 Bianca A. Allison, Tracey A. Wilkinson, Julie Maslowsky
This JAMA Insights explores how clinicians can effectively communicate person-centered health care information to adolescents regarding sexual and reproductive health, contraception, and sexually transmitted infection testing and treatment.
-
Continuous vs Intermittent β-Lactam Antibiotic Infusions for Sepsis-Reply. JAMA (IF 63.1) Pub Date : 2024-12-16 Joel M Dulhunty,Jason A Roberts,Jeffrey Lipman,
-
Continuous vs Intermittent β-Lactam Antibiotic Infusions for Sepsis. JAMA (IF 63.1) Pub Date : 2024-12-16 Jiashu Han,Queran Lin,Dan Shan
-
Adenoma Detection Rates by Physicians and Subsequent Colorectal Cancer Risk JAMA (IF 63.1) Pub Date : 2024-12-16 Nastazja D. Pilonis, Piotr Spychalski, Mette Kalager, Magnus Løberg, Paulina Wieszczy, Joanna Didkowska, Urszula Wojciechowska, Jaroslaw Kobiela, Jaroslaw Regula, Thomas Rösch, Michael Bretthauer, Michal F. Kaminski
ImportancePatients of physicians with higher adenoma detection rates (ADRs) during colonoscopy have lower colorectal cancer (CRC) risk after screening colonoscopy (ie, postcolonoscopy CRC). Among physicians with an ADR above the recommended threshold, it is unknown whether improving ADR is associated with a lower incidence of CRC in their patients.ObjectiveTo determine the association of improved ADR
-
Atrial Fibrillation JAMA (IF 63.1) Pub Date : 2024-12-16 Darae Ko, Mina K. Chung, Peter T. Evans, Emelia J. Benjamin, Robert H. Helm
ImportanceIn the US, approximately 10.55 million adults have atrial fibrillation (AF). AF is associated with significantly increased risk of stroke, heart failure, myocardial infarction, dementia, chronic kidney disease, and mortality.ObservationsSymptoms of AF include palpitations, dyspnea, chest pain, presyncope, exertional intolerance, and fatigue, although approximately 10% to 40% of people with
-
Neoadjuvant Camrelizumab for Triple-Negative Breast Cancer. JAMA (IF 63.1) Pub Date : 2024-12-13 Heikki Joensuu
-
Many Acute Care Hospital Infections Drop to Prepandemic Levels. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
Very Early Medication Abortions as Safe and Effective as Standard Timing. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
First H5N1 Bird Flu Infections in Pigs Raises Concerns. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
The Next Step in Hospital-at-Home Care Could Be Virtual. JAMA (IF 63.1) Pub Date : 2024-12-13 Avery Orrall
-
The Low-Cost, Battery-Powered AI-Enabled Ultrasound Device That Could Improve Global Obstetric Care JAMA (IF 63.1) Pub Date : 2024-12-13 Roy Perlis, Kate Schweitzer
This Medical News article is an interview with Jeffrey S. A. Stringer, MD, whose commitment to global health equity has led to advancements in artificial intelligence-enabled tools that can accurately estimate gestational age during pregnancy without trained sonographers.
-
Lp(a) Reduction, GLP-1s for Heart Failure, and More-Highlights From the AHA Scientific Sessions. JAMA (IF 63.1) Pub Date : 2024-12-13 Jennifer Abbasi
-
New Research Suggests Increased Risk of Some Autoimmune Disorders After COVID-19. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
Meta-Analysis: Nurse Burnout May Lead to Lower Quality of Care, Patient Safety. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
Trial Shows It's Safe to Get COVID-19, Flu Vaccines at the Same Time. JAMA (IF 63.1) Pub Date : 2024-12-13 Samantha Anderer
-
Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer JAMA (IF 63.1) Pub Date : 2024-12-13 Li Chen, Hui Li, Hao Zhang, Huawei Yang, Jun Qian, Zhihua Li, Yu Ren, Shu Wang, Peifen Fu, Hongjian Yang, Yunjiang Liu, Jing Sun, Jianyun Nie, Ruiwen Lei, Yongzhong Yao, Anqin Zhang, Shouman Wang, Xiaopeng Ma, Zhong Ouyang, Hongwei Yang, Song-Yang Wu, Shuo-Wen Cao, Kun Wang, Aimei Jiang, Quchang Ouyang, Da Pang, Limin Wei, Xiaoming Zha, Yu Shen, Xiangwen Qu, Fei Wu, Xiaoyu Zhu, Zhonghua Wang, Lei Fan
ImportancePreferred neoadjuvant strategies for early or locally advanced triple-negative breast cancer include a 4-drug chemotherapy regimen containing anthracyclines, cyclophosphamide, taxanes, and platinum. Blockade of the programmed death receptor 1/ligand-1 (PD-1/PD-L1) pathway may improve efficacy of classic neoadjuvant chemotherapy. Camrelizumab, an anti–PD-1 antibody, has showed antitumor activity
-
Reimagining Luck JAMA (IF 63.1) Pub Date : 2024-12-13 Danielle Novetsky Friedman
In this narrative medicine essay, a physician specializing in cancer survivorship calls for equitable cancer detection and prevention for all after developing breast cancer 5 years after genetic testing had indicated she had a variant of uncertain significance.
-
Am I a Survivor? JAMA (IF 63.1) Pub Date : 2024-12-12 Cara E. Texler
In this narrative medicine essay, a pediatric hospitalist who had undergone a double mastectomy after atypical ductal hyperplasia was detected in one of her breasts wonders whether the pain and loss from that surgery renders her a cancer survivor.
-
Paying More for Primary Care—A New Approach by Medicare JAMA (IF 63.1) Pub Date : 2024-12-12 Soleil Shah, Suhas Gondi, Amol S. Navathe
This Viewpoint discusses a new prospective payment model that supports primary care for accountable care organizations in the Medicare Shared Savings Program.
-
Trends in School Mental Health and Substance Use Education JAMA (IF 63.1) Pub Date : 2024-12-12 Chloe Gao, Donald Szlosek, Anthony Zhong, Scott E. Hadland, Sarah S. Benes
This study examines trends in school programming related to mental health and substance use and teacher professional development across US middle and high schools from 2008 to 2020.
-
Is It Time to Abandon Surgery for Low-Risk DCIS? JAMA (IF 63.1) Pub Date : 2024-12-12 Monica Morrow,Andrea V Barrio
-
Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-12-12 E Shelley Hwang,Terry Hyslop,Thomas Lynch,Marc D Ryser,Anna Weiss,Anna Wolf,Kelsey Norris,Meredith Witten,Lars Grimm,Stuart Schnitt,Sunil Badve,Rachel Factor,Elizabeth Frank,Deborah Collyar,Desiree Basila,Donna Pinto,Mark A Watson,Robert West,Louise Davies,Jenny L Donovan,Ayako Shimada,Yutong Li,Yan Li,Antonia V Bennett,Shoshana Rosenberg,Jeffrey Marks,Eric Winer,Marc Boisvert,Armando Giuliano,Kelsey
Importance Active monitoring for low-risk ductal carcinoma in situ (DCIS) of the breast has been proposed as an alternative to guideline-concordant care, but the safety of this approach is unknown. Objective To compare rates of invasive cancer in patients with low-risk DCIS receiving active monitoring vs guideline-concordant care. Design, Setting, and Participants Prospective, randomized noninferiority
-
Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer. JAMA (IF 63.1) Pub Date : 2024-12-11 Wen-Chien Cheng,Guosheng Wang,Qi Mei
-
Ivonescimab Plus Chemotherapy in Patients With EGFR Variant Non-Small Cell Lung Cancer. JAMA (IF 63.1) Pub Date : 2024-12-11 Zaoqu Liu,Dan Shan,Xinwei Han
-
Early Restrictive vs Liberal Oxygen for Trauma Patients: The TRAUMOX2 Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-12-10 Tobias Arleth,Josefine Baekgaard,Volkert Siersma,Andreas Creutzburg,Felicia Dinesen,Oscar Rosenkrantz,Johan Heiberg,Dan Isbye,Søren Mikkelsen,Peter M Hansen,Stine T Zwisler,Søren Darling,Louise B Petersen,Maria C R Mørkeberg,Mikkel Andersen,Christian Fenger-Eriksen,Peder T Bach,Mark G Van Vledder,Esther M M Van Lieshout,Niki A Ottenhof,Iscander M Maissan,Dennis Den Hartog,Wolf E Hautz,Dominik A Jakob
Importance Early administration of supplemental oxygen for all severely injured trauma patients is recommended, but liberal oxygen treatment has been associated with increased risk of death and respiratory complications. Objective To determine whether an early 8-hour restrictive oxygen strategy compared with a liberal oxygen strategy in adult trauma patients would reduce death and/or major respiratory
-
Electronic Sepsis Screening Among Patients Admitted to Hospital Wards: A Stepped-Wedge Cluster Randomized Trial. JAMA (IF 63.1) Pub Date : 2024-12-10 Yaseen M Arabi,Abdulmohsen Alsaawi,Mohammed Alzahrani,Ali M Al Khathaami,Raed H AlHazme,Abdullah Al Mutrafy,Ali Al Qarni,Ramesh Kumar Vishwakarma,Rasha Al Anazi,Eman Al Qasim,Sheryl Ann Abdukahil,Fawaz K Al-Rabeah,Huda Al Ghamdi,Abdulaleem Alatassi,Hasan M Al-Dorzi,Fahad Al-Hameed,Razan Babakr,Abdulaziz A Alghamdi,Salih Bin Salih,Ahmad Alharbi,Mufareh Edah AlKatheri,Hani Mustafa,Saad Al-Qahtani,Shaher
Importance Sepsis screening is recommended among hospitalized patients but is supported by limited evidence of effectiveness. Objective To evaluate the effect of electronic sepsis screening, compared with no screening, on mortality among hospitalized ward patients. Design, Setting, and Participants In a stepped-wedge, cluster randomized trial at 5 hospitals in Saudi Arabia, 45 wards (clusters) were
-
High-Flow Nasal Oxygen vs Noninvasive Ventilation in Patients With Acute Respiratory Failure: The RENOVATE Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-12-10 ,Israel S Maia,Letícia Kawano-Dourado,Lucas Tramujas,Neymar Elias de Oliveira,Rafael Naoki Souza,Dhaisi Faustino Signorini,Mariangela Pimentel Pincelli,Cássio Luis Zandonai,Regiane Tamires Blasius,Fabrício Freires,Vanessa Marques Ferreira,Marcelo Luz Pereira Romano,Mieko Claudia Miura,Caroline Maschio de Censo,Eliana Bernadete Caser,Betania Silva,Daniela Correia Santos Bonomo,Jussara Alencar Arraes
Importance High-flow nasal oxygen (HFNO) and noninvasive ventilation (NIV) are commonly used respiratory support therapies for patients with acute respiratory failure (ARF). Objective To assess whether HFNO is noninferior to NIV on the rates of endotracheal intubation or death at 7 days in 5 patient groups with ARF. Design, Setting, and Participants This noninferiority, randomized clinical trial enrolled
-
Reevaluating Respiratory Support in Acute Respiratory Failure-Insights From the RENOVATE Trial and Implications for Practice. JAMA (IF 63.1) Pub Date : 2024-12-10 Yonathan Freund,Amelie Vromant
-
Is High-Flow Oxygen the Standard for All Patients With Acute Respiratory Failure? JAMA (IF 63.1) Pub Date : 2024-12-10 Jean-Pierre Frat,Sylvain Le Pape,Arnaud W Thille
-
The Urgent Case for Recommitting to Global HIV/AIDS Goals JAMA (IF 63.1) Pub Date : 2024-12-10 Carlos del Rio, Victor Dzau
This Viewpoint discusses the need to recommit to the fight against HIV/AIDS to reach the United Nation’s 2030 goal of ending the epidemic as a public health threat.
-
Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial. JAMA (IF 63.1) Pub Date : 2024-12-09 Paul Dark,Anower Hossain,Daniel F McAuley,David Brealey,Gordon Carlson,Jonathan C Clayton,Timothy W Felton,Belinder K Ghuman,Anthony C Gordon,Thomas P Hellyer,Nazir I Lone,Uzma Manazar,Gillian Richards,Iain J McCullagh,Ronan McMullan,James J McNamee,Hannah C McNeil,Paul R Mouncey,Micheal J Naisbitt,Robert J Parker,Ruth L Poole,Anthony J Rostron,Mervyn Singer,Matt D Stevenson,Tim S Walsh,Ingeborg D
Importance For hospitalized critically ill adults with suspected sepsis, procalcitonin (PCT) and C-reactive protein (CRP) monitoring protocols can guide the duration of antibiotic therapy, but the evidence of the effect and safety of these protocols remains uncertain. Objective To determine whether decisions based on assessment of CRP or PCT safely results in a reduction in the duration of antibiotic
-
Loneliness and Social Isolation Among US Older Adults. JAMA (IF 63.1) Pub Date : 2024-12-09 Preeti N Malani,Erica Solway,Matthias Kirch,Dianne C Singer,J Scott Roberts,Jeffrey T Kullgren
-
Lessons Learned From E-Cigarettes Should Affect FDA Regulation of Nicotine Pouches JAMA (IF 63.1) Pub Date : 2024-12-09 Cristine D. Delnevo, Mary Hrywna
This JAMA Viewpoint investigates the rising popularity of nicotine pouches, especially among youths, and how the US Food and Drug Administration must act quickly to regulate these products and curb market growth.
-
Bullets as Pathogen—The Need for Public Health and Policy Approaches JAMA (IF 63.1) Pub Date : 2024-12-09 Eric W. Fleegler, Laura Vargas, Christian D. Pulcini, Stephen Hargarten
This JAMA Viewpoint explores how public health principles related to communicable diseases and bullet-specific regulations could be applied in the US to prevent further injury and death due to gun violence.
-
What to Expect From a Low-Nicotine Product Standard for Cigarettes JAMA (IF 63.1) Pub Date : 2024-12-09 Rachel L. Denlinger-Apte, Cassidy M. White, Eric C. Donny
This Viewpoint discusses the public health benefits that could be gained if the US Food and Drug Administration (FDA) were to mandate very low-nicotine-content cigarettes (VLNCs).
-
New Global Tuberculosis Cases Hit Record High. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
CDC Recommends Lowering the Pneumococcal Vaccine Age to 50. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
Colonoscopies Outperform New Blood Tests for Colon Cancer Screening. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
Climate Change Inaction Poses Record-Breaking Health Risks. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
US Government Turns to Retail Pharmacies to Improve Representation in Clinical Trials. JAMA (IF 63.1) Pub Date : 2024-12-06 Kate Ruder
-
CDC Recommends Second COVID-19 Vaccine Dose for Older Adults. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
Semaglutide Eases Knee Osteoarthritis Pain in People With Obesity. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
Researcher Explores Using AI to Overcome Language Barriers With Patients JAMA (IF 63.1) Pub Date : 2024-12-06 Yulin Hswen, Kate Schweitzer
This Medical News article is an interview with K. Casey Lion, MD, MPH, about the need for greater equity in health care for those with language barriers and how artificial intelligence translation tools may help bridge the gap.
-
Brain Stimulation With Cognitive Remediation Might Slow Cognitive Decline in Depression. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
US Triplet and Higher-Order Birth Rate Down 62% Since 1998. JAMA (IF 63.1) Pub Date : 2024-12-06 Samantha Anderer
-
Diversion of Undistributed Pharmaceutical Ketamine in the US. JAMA (IF 63.1) Pub Date : 2024-12-05 Joseph J Palamar,Caroline Rutherford,Katherine M Keyes
-
Redefining Resilience JAMA (IF 63.1) Pub Date : 2024-12-05 Julie B. Trivedi
In this narrative medicine essay, an infectious diseases physician shares how her journey to and through a depressive episode led her to raise awareness of mental health challenges and to help create supportive working environments.
-
Obstetric Care Access at Rural and Urban Hospitals in the United States. JAMA (IF 63.1) Pub Date : 2024-12-04 Katy B Kozhimannil,Julia D Interrante,Caitlin Carroll,Emily C Sheffield,Alyssa H Fritz,Alecia J McGregor,Sara C Handley
-
-
Firearm Policy in the Hospital Setting-Reply. JAMA (IF 63.1) Pub Date : 2024-12-04 Joshua B Romero,Richard S Saver,Joseph Blocher
-
Axial Spondyloarthritis JAMA (IF 63.1) Pub Date : 2024-12-04 Mohamad Bittar, Atul Deodhar
ImportanceAxial spondyloarthritis is an immune-mediated inflammatory condition involving the sacroiliac joints, spine, and peripheral joints. It affects approximately 1% of adults in the US and is associated with impaired physical function and reduced quality of life.ObservationsInflammatory chronic back pain characterized by gradual onset starting before age 45 years, prolonged morning stiffness,
-
California’s Visionary Tobacco Bill—Will the FDA Follow? JAMA (IF 63.1) Pub Date : 2024-12-02 Sven E. Jordt, Sairam V. Jabba
This Viewpoint discusses California’s new law that will further strengthen tobacco control and whether the FDA and other states will follow California’s example.